Physician profile
Matthew E Price
NPI 1528118551
$15,992.85
in general payments reported to CMS, 2019-2025
27 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $93.42 · 2021: $303 · 2022: $1,917 · 2023: $13K · 2024: $230 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $11K · Travel and Lodging: $1,962 · Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,519.27 |
| Travel and Lodging | $1,962.40 |
| Food and Beverage | $979.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,790.58 | 2023 | Davinci Xi, Da Vinci Surgical System, Da Vinci Sp |
| Boston Scientific Corporation | $1,718.88 | 2022 | |
| Mayne Pharma Commercial LLC | $200.00 | 2021 | |
| Pfizer INC. | $182.37 | 2019-2023 | |
| Astellas Pharma US INC | $127.90 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $114.09 | 2022-2024 | |
| Ethicon US, LLC | $109.84 | 2023-2025 | Enseal X1, Echelon; Endopath |
| Allergan, INC. | $100.28 | 2019-2021 | |
| Aspira Women'S Health INC | $90.08 | 2024 | Ova1 |
| Sumitomo Pharma America, INC. | $78.11 | 2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $71.09 | 2019-2020 | |
| Organon LLC | $63.41 | 2022-2025 | Nexplanon |
| Medtronic, INC. | $61.53 | 2021-2025 | Interstim, Truclear |
| Davol INC. | $41.53 | 2022 | |
| Hologic Sales and Service, LLC | $32.99 | 2019-2023 | Aptima |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $32.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.20 | 2019-2020 | |
| Coopersurgical, INC. | $21.71 | 2023 | Paragard T 380a |
| Biogen, INC. | $21.11 | 2024 | |
| Shield Therapeutics INC | $17.36 | 2023 | Accrufer |
| Amgen INC. | $15.65 | 2024 | Evenity, Prolia |
| Pacira Pharmaceuticals Incorporated | $13.55 | 2020 | |
| Solventum Corporation | $13.54 | 2024 | Prevena |
| Therapeuticsmd, INC. | $13.52 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.47 | 2019 | |
| Daiichi Sankyo INC. | $11.43 | 2021 | |
| Smith+Nephew, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.